NCT01736709

The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine

A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: Sinovac Biotech Co., Ltd · Industry
• Sex: All
• Age: 6 Months – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy older people aged \> 60 years.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	2012-2013 trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-04-01
• Completion: 2013-05-01
• First posted: 2012-11-29
• Last updated: 2013-05-29

Locations

1 site across 1 country: China